Skip to main content

Featured

Sept 15 Tariff Shift: What's Actually Changing on Canadian Goods (And What Isn't)

  Published September 12, 2026 At 12:01 a.m. ET on Tuesday, September 15, a new round of U.S. tariff changes takes effect on Canadian goods. If you've seen headlines calling this a "new 50% tariff on Canadian steel, aluminum and paper," here's the more accurate story: it isn't a new tariff at all. It's the U.S. reshuffling which products fall under a 50% tariff that's already been in place since August 22 — adding some categories, removing others, on the same day. Here's what's actually happening, and why it matters more to Canadian manufacturers and cross-border shoppers than to your everyday grocery bill. The tariff this modifies Back on August 22, 2026, the U.S. imposed a 50% tariff under Section 338 of the Tariff Act of 1930 on roughly $20 billion CAD of Canadian goods. The White House framed it as retaliation for Canadian "discrimination" against U.S. alcoholic beverages, dairy, and motor vehicles — three separate proclamations, eac...
Post a Comment
Read more

article

Labels

Controversial Turkish Import Endangers Newborns in Alberta, Documents Reveal

 

Recent documents have raised alarming concerns over Alberta’s emergency importation of children’s pain medication from Turkey. Produced by Atabay Pharmaceuticals and sold under the brand name Parol Suspension, the drug is marketed at a concentration of 24 mg/ml—significantly lower than the 32 mg/ml concentration found in the standard, Canadian-authorized formulation.

Health experts and opposition critics warn that this altered concentration poses a twofold risk. First, the discrepancy could lead to dosing errors if parents and caregivers, accustomed to the standard formulation, misjudge the correct volume needed. Second, there are fears that the lower concentration may lead to the clogging of hospital feeding tubes—a critical concern for vulnerable newborns.

Alberta Blue Cross has informed pharmacists that Parol must be dispensed with enhanced caution, requiring additional education on its proper use. Critics argue that the rushed procurement—amounting to approximately $80 million—exemplifies a misstep in prioritizing political expedience over stringent safety protocols. With traditional supplies of children’s pain medications already in short supply, many worry that this controversial alternative might jeopardize the health of Alberta’s youngest patients.

Further review and tighter regulatory oversight are now being called for, as stakeholders demand that the province safeguard the well-being of newborns and ensure that emergency measures do not compromise pediatric care.

Labels:

Comments

Post a Comment